Abstracts

Click on the boxes below to access abstract information

Abstract deadlines

Abstract submission deadline

10 January 2023 at 11.59 p.m Eastern Time US

Late-Breaking abstract submission period

01-31 March 2023

Late-Breaking Abstract Submission Period: 01-31 March 2023

There will also be an Oral Concurrent session made up of 12 chosen Late-Breaking submissions (as selected by the aforementioned Scientific Program Committee) presented during the Meeting.

Additional information will be made available in February detailing the submission process

Submissions

  • All abstracts must be submitted online through the abstract submission system by the posted deadline to be considered for acceptance.  No fax copies, disk or e-mail submissions will be accepted. 
  • You can enter your abstract, save it, and return for edits or updates any time prior to the deadline.  The Complete Payment button must be clicked before the deadline.  Changes to abstract titles or abstract text, as well as additions or deletions of author names, will NOT be permitted after submission. Proofread your abstract to identify and correct any errors before submission.
  • Only the individual listed as the official contact of the submission has authority to withdraw it or revise content. If an abstract must be withdrawn after submission, requests must be received no later than February 22, 2023. To withdraw your abstract, email abstracts@sidnet.org and include your name, abstract control ID# (7-digits) and abstract title. 
  • Submission of an abstract constitutes a commitment by the author(s) to present their work if the abstract is accepted.  Authors of accepted abstracts are expected to register for the ISID Meeting and pay the meeting registration fee.

Abstract guidelines

RULES AND REGULATIONS

  • The material must not have been published prior to submission of the abstract or presented at any national meeting prior to the date of presentation at the Meeting. Simultaneous submission of the same abstract to other meetings is prohibited. If there is a real or perceived conflict of interest pertaining to your abstract or presentation, especially one of personal or departmental financial benefit, please provide this information on this site.
  • Only one paper or poster may be read or presented by the same author at the Meeting, although a presenter may be a co-author of any number of papers.
  • There is a limit of 2,300 characters for the text of your abstract submission (title, authors, institutions, abstract body, and all spaces will be counted).

ABSTRACT FEE

The publication/processing fee is US $50 and must be paid via the internet at the time of submission.

PUBLICATION OF ABSTRACTS

  • Abstracts accepted for presentation at the ISID 2023 Meeting will be published in the May 2023 Supplement issue of the Journal of Investigative Dermatology (JID) and Journal of Investigative Dermatology Innovations (JIDI) and will appear as they are submitted.
  • Authors retain copyright in their abstracts and grant the Society for Investigative Dermatology an exclusive license to publish their submission in the Journal of Investigative Dermatology.

REVIEW PROCESS

After the abstract submission deadline, all abstracts will be reviewed by the ISID Abstract Review Committee, plus six independent reviewers for each category topic.  The committee reviews all abstracts without knowing the identity of authors. 

PRESENTATION

All accepted abstracts will be selected for presentation during one of four session types:  Plenary (up to 15 minutes oral presentation), Concurrent Mini-Symposium (up to 12 minutes oral presentation), e-Poster Discussion (up to 6 minutes oral presentation), and Poster Only.

    • All oral presenters (Plenary, Mini-Symposium, e-Poster) will also be required to upload an electronic poster of their abstract (PDF).  Details on electronic uploads will be shared in advance of the meeting

    • Poster Only presenters will be required to bring a hard copy of their poster for display in the Poster Hall and participate in their assigned Poster Session on either the Thursday or Friday of the meeting.  This information will be available when abstract status notifications are posted in February 2023.

Grants / Scholarships

Travel Grants will be awarded to investigators who will attend the ISID 2023 Meeting to present their scientific work.
For more information on grants eligibility and criteria please see the “Grants” page here

The ISID Organising committee is grateful to the travel grants supporters for their generous support of travel grants to attend ISID 2023.

Abstract FAQ

Important information

you should know

Abstract submissions will close Tuesday, January 10, 2023, at 11:59 PM Eastern Time US

A non-refundable $50.00 (fifty U.S. dollars) processing fee is required for each abstract submitted, payable online only. Purchase orders, checks, and electronic bank transfers will not be accepted. 

The abstract submission fee is non-refundable whether the abstract is accepted for presentation or not. There are NO exceptions.

Your abstract may contain no more than 2,300 characters (title, authors, institutions, abstract body and all spaces will be counted). The submission site will automatically calculate your abstract’s characters and notify you if the submission exceeds the maximum character limit.

Yes, you may log back into the submission system as often as necessary until 11:59 PM Eastern Time on Tuesday, January 10, 2023, to edit your abstract. After this date, you may not revise or resubmit an abstract in order to make corrections.

Only one paper or poster may be read or presented by the same author at the Meeting, although a presenter may be a co-author of any number of papers.

Notification of the status of abstracts will be sent electronically to the official contact and presenter in mid-February, 2023. 

If you decide to withdraw your abstract prior to the submission and editing deadline (11:59 PM Eastern Time US on Tuesday, January 10, 2023, you may log into the abstract submission system and withdraw your abstract there. After this deadline, if an abstract must be withdrawn, requests must be received no later than February 22, 2023.

To withdraw your abstract, email abstracts@sidnet.org and include your name, abstract control ID# (7-digits) and abstract title.

Please contact abstracts@sidnet.org with additional questions.

ISID 2023 Meeting attendees will need to comply with both local and national health mandates at the time of the in-person meeting. Unless otherwise indicated or subsequently communicated, ISID 2023 will not require COVID vaccinations nor the use of face-masks.

For Coronavirus-related information click here

Abstract categories

Adaptive and Auto-Immunity: Studies of adaptive immune responses involving T and B lymphocytes, dendritic cells, other antigen presenting cells, and antigen processing and presentation; Basic and pre-clinical experimental studies focused on autoimmunity.

Artificial Intelligence (AI) and Image Analysis: Use of artificial intelligence and machine learning in healthcare; Technologies used for medical imaging and diagnostics.

Carcinogenesis and Cancer Genetics: Studies on the genetics and other causes of cancer as well as mechanisms relevant to metastasis (Abstracts on therapeutics and clinical trials in skin cancer should be submitted to Translational Studies or Clinical Research – Interventional Research).


Cell-Cell Interactions in the Skin: Studies on cell-cell interactions between specific skin cell types (including but not limited to keratinocytes, nerves (neuro-cutaneous biology), melanocytes, fibroblasts, adipocytes, immune cells and progenitors) in the skin and their local cellular and extracellular environments that affect skin inflammation, sensation (e.g., itch and pain), signaling, adhesion, migration, development and homeostasis.

Clinical Research – Epidemiology and Observational Research: Non-interventional studies of populations or patient cohorts that evaluate, but are not limited to, the natural history of disease, disease burden, co-morbidities, health-related quality of life, and patient-reported outcomes research.

Clinical Research – Interventional Research: Interventional human trials that evaluate or compare therapies, devices, or other interventions for the treatment of skin diseases. This may include systematic reviews and/or meta-analyses of interventional studies.

Clinical Research – Socio-behavioral and Health Services Research: Socio-behavioral studies may include, but are not limited to, studies of patient and/or provider behaviors and attitudes towards diseases, treatments, diagnostic and screening tests, and health care delivery. Health services research studies may include, but are not limited to, studies of access, use, delivery, quality, and cost-effectiveness of dermatologic care.

COVID-19 and Dermatological Research: Current knowledge on COVID-19-associated cutaneous manifestations, clinical features and therapeutic management, and pathophysiological mechanisms of these conditions.

Epidermal Structure and Barrier Function: Research on the components or regulation of keratinocyte proliferation, differentiation, including epidermal barrier maintenance and function.

Genetic Disease, Gene Regulation and Gene Therapy: Studies on cutaneous gene expression (including genomic based studies) and genetic diseases including gene therapy (Cancer-related genetic studies are more appropriate for Carcinogenesis and Cancer Genetics).

Innate Immunity, Microbiology, Microbiome: Studies of cells, receptors and effector molecules of the innate immune response; studies on skin microbes, microbiome and infectious processes of the skin.

Pharmacology and Drug Development: Basic and preclinical studies aimed at developing therapeutics, elucidating their mechanisms of action, and identifying biomarkers of drug activity.

Photobiology: Studies on biological, biochemical, and molecular responses to ultraviolet radiation in cells, animals and humans.

Pigmentation & Melanoma: Studies on all aspects of cutaneous and extracutaneous pigmentation; molecular cellular and biological facets of melanoma. (Genetic studies on melanoma should be considered for the category Carcinogenesis and Cancer Genetics).

Skin, Appendages, and Stem Cell Biology: Studies on the hair follicle, sebaceous gland, and other skin appendages; developmental biology of skin and hair; roles of stem cells in pre and post-natal growth and development.

Skin of Color: Studies of the pathogenesis or treatment of skin diseases that disproportionately affect patients from, or are more severe in their manifestation in, racial/ethnic groups with skin of color; such as keloids, scarring alopecias, disorders of pigmentation, systemic lupus erythematosus, dermatomyositis, among others.

Tissue Regeneration & Wound Healing: Wound healing and regeneration studies; processes/signaling that regulate vascular development and angiogenesis; interactions between different skin components that contribute to the functional process of wound healing or tissue regeneration.

Translational Studies: Studies that translate basic research findings into human model systems (i.e. human tissue and/or cells) or humans.

MEETING STARTS IN

Days
Hours
Minutes